Seth Lederman Purchases 2,000 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman acquired 2,000 shares of the business’s stock in a transaction dated Thursday, August 27th. The stock was acquired at an average price of $13.79 per share, for a total transaction of $27,580.00. Following the completion of the transaction, the chief executive officer owned 11,005 shares in the company, valued at approximately $151,758.95. The trade was a 22.21% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Seth Lederman also recently made the following trade(s):

• On Tuesday, June 9th, Seth Lederman bought 5,000 shares of Tonix Pharmaceuticals stock. The shares were acquired at an average cost of $11.79 per share, for a total transaction of $58,950.00.

Tonix Pharmaceuticals Stock Down 0.9%

Shares of Tonix Pharmaceuticals stock opened at $13.98 on Wednesday. The business has a 50 day moving average of $12.06 and a 200 day moving average of $12.95. Tonix Pharmaceuticals Holding Corp. has a 52 week low of $9.40 and a 52 week high of $31.55. The company has a market cap of $239.76 million, a PE ratio of -1.08 and a beta of 1.74.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Monday, August 10th. The company reported ($2.44) earnings per share for the quarter, beating the consensus estimate of ($2.64) by $0.20. The business had revenue of $13.54 million for the quarter, compared to analysts’ expectations of $7.72 million. Tonix Pharmaceuticals had a negative net margin of 548.64% and a negative return on equity of 68.99%. On average, research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -10.03 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Legal & General Group Plc purchased a new position in Tonix Pharmaceuticals during the 2nd quarter valued at about $25,000. State of Wyoming purchased a new stake in Tonix Pharmaceuticals in the fourth quarter worth about $27,000. Russell Investments Group Ltd. bought a new position in shares of Tonix Pharmaceuticals during the third quarter valued at approximately $29,000. California State Teachers Retirement System lifted its holdings in shares of Tonix Pharmaceuticals by 221.9% during the second quarter. California State Teachers Retirement System now owns 2,437 shares of the company’s stock valued at $31,000 after purchasing an additional 1,680 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in shares of Tonix Pharmaceuticals during the second quarter valued at approximately $65,000. 82.26% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on TNXP. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings lowered shares of Tonix Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. TD Cowen raised Tonix Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, May 5th. Finally, Raymond James Financial reissued a “strong-buy” rating and issued a $27.00 target price on shares of Tonix Pharmaceuticals in a research report on Monday, August 10th. Two investment analysts have rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $24.50.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.